A surge in clinical trials investigating potential idiopathic pulmonary fibrosis therapies offers patients new hope, according to a recently published review.

Chugai files regulatory application with Japanese MHLW for additional indication of Tecentriq to treat thymic carcinoma: Tokyo Tuesday, May 20, 2025, 15:00 Hrs [IST] Chugai Pharma ...